prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55 |56 |review

Short-acting analogs: Onset - 15 min. Peak - 1-2 hrs. Duration: 4-6 hrs.

Reg.: Onset - 30 - 60 min. Peak:2-4 hrs. Duration: 6-8 hrs.

Glargine: Onset - 2-4 hrs.  Peak: flat.  Duration: 24 hrs

R

 

Insulin analogues offer a much more physiologic insulin profile than do older insulin preparations and allow development of a treatment strategy that gives patients much more dietary freedom using a basal-bolus insulin with carbohydrate counting.

 

CSII provides the ultimate in physiologic insulin delivery and will soon be linked to a continuous glucose monitoring technology that brings insulin treatment closer to the dream of a closed loop system or “artificial pancreas”.